SUPN

SEC source: 0001836067-25-000006 · wk-form4_1758917846.xml · nonDerivative · entry 2

Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,015

F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.

SEC source: 0001836067-25-000006 · wk-form4_1758917846.xml · nonDerivative · entry 1

Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,855

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2024.

SEC source: 0001539937-25-000020 · wk-form4_1758744856.xml · derivative · entry 4

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 47,940 shares

Expires 2026-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested in four equal installments beginning on March 1, 2017.

SEC source: 0001539937-25-000020 · wk-form4_1758744856.xml · nonDerivative · entry 2

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,140,883

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.55. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001539937-25-000020 · wk-form4_1758744856.xml · nonDerivative · entry 1

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,170,396

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024.

SEC source: 0001539937-25-000018 · wk-form4_1758658919.xml · derivative · entry 4

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,940

Underlying: Common Stock · 27,060 shares

Expires 2026-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested in four equal installments beginning on March 1, 2017.

SEC source: 0001539937-25-000018 · wk-form4_1758658919.xml · nonDerivative · entry 2

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,122,456

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.08. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001539937-25-000018 · wk-form4_1758658919.xml · nonDerivative · entry 1

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,139,043

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024.

SEC source: 0001804567-25-000006 · wk-form4_1757972337.xml · derivative · entry 3

Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2028-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 14, 2019 .

SEC source: 0001804567-25-000006 · wk-form4_1757972337.xml · nonDerivative · entry 2

Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,496

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.73 to $45.96. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001804567-25-000006 · wk-form4_1757972337.xml · nonDerivative · entry 1

Mottola Frank · CIK 0001804567 · SVP, Chief Tech. Ops. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,496

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001836067-25-000004 · wk-form4_1757707628.xml · derivative · entry 2

Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,875

Underlying: Common Stock · 1,875 shares

Expires not disclosed

F2 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.

F2 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.

SEC source: 0001539937-25-000016 · wk-form4_1757707550.xml · derivative · entry 4

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,320

Underlying: Common Stock · 19,320 shares

Expires not disclosed

F2 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.

F2 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024.

SEC source: 0001539937-25-000016 · wk-form4_1757707550.xml · derivative · entry 3

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires not disclosed

F1 · derivative.exercise_date: On February 19, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on April 30, 2021.

F1 · derivative.expiration_date: On February 19, 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on April 30, 2021.

SEC source: 0001539937-25-000014 · wk-form4_1757449275.xml · derivative · entry 3

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 162,500

Underlying: Common Stock · 8,074 shares

Expires 2027-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018

SEC source: 0001539937-25-000014 · wk-form4_1757449275.xml · nonDerivative · entry 2

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,111,983

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.40. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001539937-25-000014 · wk-form4_1757449275.xml · nonDerivative · entry 1

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,118,305

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024.

SEC source: 0001539937-25-000012 · wk-form4_1757363472.xml · derivative · entry 4

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 170,574

Underlying: Common Stock · 73,176 shares

Expires 2027-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018.

SEC source: 0001539937-25-000012 · wk-form4_1757363472.xml · nonDerivative · entry 2

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,110,231

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.09. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001539937-25-000012 · wk-form4_1757363472.xml · nonDerivative · entry 1

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,165,809

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024.

SEC source: 0001539937-25-000010 · wk-form4_1756497941.xml · derivative · entry 7

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 38,779 shares

Expires 2026-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option vested in four equal installments beginning on March 1, 2017.

SEC source: 0001539937-25-000010 · wk-form4_1756497941.xml · nonDerivative · entry 4

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,092,633

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.26. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001539937-25-000010 · wk-form4_1756497941.xml · nonDerivative · entry 3

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,116,783

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024.

SEC source: 0001005544-25-000008 · wk-form4_1756497902.xml · nonDerivative · entry 1

NEWHALL CHARLES W III · CIK 0001005544 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 129,644

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted March 3, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.04. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001539937-25-000010 · wk-form4_1756497941.xml · derivative · entry 6

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 113,779

Underlying: Common Stock · 17,195 shares

Expires 2026-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option vested in four equal installments beginning on March 1, 2017.

SEC source: 0001539937-25-000010 · wk-form4_1756497941.xml · nonDerivative · entry 2

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,078,004

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.10. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001539937-25-000010 · wk-form4_1756497941.xml · nonDerivative · entry 1

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,088,654

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024.

SEC source: 0001005544-25-000006 · wk-form4_1756328215.xml · nonDerivative · entry 1

NEWHALL CHARLES W III · CIK 0001005544 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 133,232

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted March 3, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.01. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001804567-25-000004 · wk-form4_1756328373.xml · derivative · entry 3

Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,000 shares

Expires 2026-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vests in four equal annual installments beginning on March 1, 2017.

SEC source: 0001804567-25-000004 · wk-form4_1756328373.xml · nonDerivative · entry 2

Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,496

F2 · shares: The Reporting Person exercised the options indicated herein and sold the underlying shares prior to the expiration of such options on March 1, 2026.

SEC source: 0001804567-25-000004 · wk-form4_1756328373.xml · nonDerivative · entry 1

Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,496

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes an aggregate of 345 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.

SEC source: 0001539215-25-000004 · wk-form4_1756328458.xml · derivative · entry 3

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.

F3 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.

SEC source: 0001539215-25-000004 · wk-form4_1756328458.xml · nonDerivative · entry 2

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,718

F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.

SEC source: 0001539215-25-000004 · wk-form4_1756328458.xml · nonDerivative · entry 1

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,299

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023.

SEC source: 0001539937-25-000008 · wk-form4_1756328164.xml · derivative · entry 4

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 130,974

Underlying: Common Stock · 1,611 shares

Expires 2026-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested in four equal installments beginning on March 1, 2017.

SEC source: 0001539937-25-000008 · wk-form4_1756328164.xml · nonDerivative · entry 2

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,071,459

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.01. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001539937-25-000008 · wk-form4_1756328164.xml · nonDerivative · entry 1

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,072,459

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024.

SEC source: 0001005544-25-000004 · wk-form4_1756239595.xml · nonDerivative · entry 1

NEWHALL CHARLES W III · CIK 0001005544 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 134,232

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted March 3, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.01, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001194020-25-000004 · wk-form4_1756239508.xml · nonDerivative · entry 1

DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,246

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.40 to $44.66, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes an aggregate of 345 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.

SEC source: 0001539937-25-000006 · wk-form4_1756238931.xml · derivative · entry 4

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 132,585

Underlying: Common Stock · 2,415 shares

Expires 2026-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested in four equal installments beginning on March 1, 2017.

SEC source: 0001539937-25-000006 · wk-form4_1756238931.xml · nonDerivative · entry 2

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,070,848

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.01. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001539937-25-000006 · wk-form4_1756238931.xml · nonDerivative · entry 1

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,072,348

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted November 14, 2024.

SEC source: 0001628280-25-040662 · wk-form4_1755548919.xml · nonDerivative · entry 1

Hudson Frederick M. · CIK 0001438462 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,307

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.14 to $42.37. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001628280-25-040668 · wk-form4_1755549074.xml · nonDerivative · entry 1

Sensenig Bethany · CIK 0001899935 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted May 15, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.88 to $42.52. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001628280-25-039308 · wk-form4_1754685809.xml · derivative · entry 2

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,250

Underlying: Common Stock · 1,250 shares

Expires not disclosed

F2 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.

F2 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023.

SEC source: 0001628280-25-039302 · wk-form4_1754685598.xml · derivative · entry 10

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 243,750

Underlying: Common Stock · 81,250 shares

Expires 2027-02-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018

SEC source: 0001628280-25-039302 · wk-form4_1754685598.xml · derivative · entry 9

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 135,000

Underlying: Common Stock · 60,000 shares

Expires 2026-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option vested in four equal installments beginning on March 1, 2017.

SEC source: 0001628280-25-039302 · wk-form4_1754685598.xml · derivative · entry 8

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 195,000

Underlying: Common Stock · 60,000 shares

Expires 2026-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option vested in four equal installments beginning on March 1, 2017.

SEC source: 0001628280-25-039302 · wk-form4_1754685598.xml · nonDerivative · entry 6

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,069,933

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.56. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001628280-25-039302 · wk-form4_1754685598.xml · nonDerivative · entry 5

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,133,433

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022.